Dr. Frick’s collaboration with colleagues at Marquette University and Concordia University Wisconsin to develop new ERbeta-specific drugs for relieving menopausal symptoms and reducing dementia risk was profiled on TMJ4 News and in a more detailed interview on Facebook. The collaboration has spawned a new company, Estrigenix Therapeutics, Inc., whose mission is to license these compounds for pharmaceutical development.  Dr. Frick is a co-founder and the Chief Scientific Officer of Estrigenix.